INVO files S-4 registration, prelim joint proxy related merger with NAYA

INVO Bioscience, which has recently signed a definitive merger agreement with NAYA Biosciences to establish an expanded, publicly traded life science company, announced that it has filed S-4 registration and preliminary joint proxy statements in connection with the upcoming merger. NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024. The additions to the board join Chairman and Chief Executive Officer Dr. Daniel Teper, Vice Chairman Dr. Peter Kash, and Director Gilles Seydoux and will continue post-merger as part of the combined company alongside current INVO CEO Steve Shum. “NAYA is thrilled to welcome new board members with outstanding executive and entrepreneurial track records,” commented NAYA CEO Dr. Daniel Teper. “As we prepare for our merger with INVO, their experience will be key in helping the management team structure our group of companies and secure financing to advance our ambitious growth strategy for 2024 and beyond. Upon closing of the merger with INVO, the NAYA leadership team will focus on scaling up the fertility business through clinic acquisitions and revamped commercialization of INVOcell, advancing the clinical development of our oncology assets, and building our regenerative medicine portfolio.” New NAYA Board Members: Laurent Audoly; Lyn Falconio; Prakash Raman; Mark Rothera; Patrick Tricoli.